Collectively, these results indicate that the co-administration of PQR309 and gemcitabine exerts synergistic anti-NPC activity through the regulation of the GSK-3β, p-STAT3/HSP60 axis. The gene discussed is HSPD1; the disease is nasopharyngeal carcinoma.